Société
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Designed with and for screening professionals, MagIA brings a solution answering to the limits of POCT screening by allowing a syndromic, multiplex diagnostic approach on portable, autonomous device for up to 6 analyses in 20mn with a blood drop.
Grenoble, Auvergne-Rhône-Alpes, France
Envoyer un message
Anglais
Français
Anglais
Français
Infectious diseases, caused by the transmission of a pathogen such as bacteria, viruses, parasites, kill millions of people each year. Eradicate them is one of the biggest health priority worldwide (WHO, governments). Effective, accessible, massive screening solutions for the management of these diseases is the key. To treat, you need to screen. Today, we do not diagnose enough. One of the challenges of the 21st century is to find “the missing millions” people.
Most of the...
Infectious diseases, caused by the transmission of a pathogen such as bacteria, viruses, parasites, kill millions of people each year. Eradicate them is one of the biggest health priority worldwide (WHO, governments). Effective, accessible, massive screening solutions for the management of these diseases is the key. To treat, you need to screen. Today, we do not diagnose enough. One of the challenges of the 21st century is to find “the missing millions” people.
Most of the infectious disease diagnostic is still done in laboratories. Many manufacturers and healthcare practitioners have been pushing for decades to change that paradigm and to decentralize testing in what is called Point-Of-Care Testing (POCT) technologies, with out of lab, portables devices. But despite the enthusiasm for POCT, their adoption by clinicians remains limited : strips tests are mostly mono-parametric, benchtop devices have limited portability, lab-on-chips suffer from manufacturing complexity and high prices …
Thanks to its micro-magnetic patented technology (6 patents) resulting from 15 years of research at CNRS, MagIA brings a solution answering to the limits of POCT screening. Designed with and for screening professionals, it allows a syndromic, multiplex diagnostic approach on truly portable, autonomous device for up to 6 analyses within 20mn using 50µL of capillary blood. In MagIA, we rather talk about On-the-Spot Screening as the solution is about reaching out-of-care populations.
1
Followers
Débute le 06-17 : Ilab award 150K€
06-17 : Ilab award 150K€
MAGIA recieved the prestigious ILAB grant from the French Ministry of Research and innovation
MAGIA's Launch
MAGIA is launched the 28-07-2017 with an interdisciplinary team of cofounders bounded by core values
12/07 : First orders
MAGIA Filed his 4 first orders, That validates MagIA's offer.
17-12 : Lab Prototype
MAGIA has completed his lab prototype along with first research grade cartridge batches
à suivre…